HMN-176, an Active Metabolite of the Synthetic Antitumor Agent HMN-214, Restores Chemosensitivity to Multidrug-Resistant Cells by Targeting the Transcription Factor NF-Y

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6942-6947

  Tanaka, Hideki ^a   Ohshima, Nobuko ^b   Ikenoya, Mami ^c   Komori, Kinuyo ^a   Katoh, Fumitaka ^a   Hidaka, Hiroyoshi ^d  

^a NIPPON SHINYAKU CO LTD   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^d D Western Therapeutics Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [2 [N ACETYL N (4 METHOXYBENZENESULFONYL)AMINO]STILBAZOLE]] 1 OXIDE; 4 [[2 N (4 METHOXYBENZENESULFONYL)AMINO]STILBAZOLE] 1 OXIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; DRUG METABOLITE; GENOMIC DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HMN 176; HMN 214; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR FACTOR Y; PACLITAXEL; RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BENZYLIDENE COMPOUNDS; CCAAT-BINDING FACTOR; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION; GENES, MDR; HELA CELLS; HUMANS; KB CELLS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROTEIN BINDING; PYRIDINES;

EID: 0142188694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bourhis, J., Goldstein, L. J., Riou, G., Pastan, I., Gottesman, M. M., and Benard, J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res., 49: 5062-5065, 1989.
2. Gottesman, M. M., and Paslan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
3. Chin, K. V., Pastan, I., and Gottesman, M. M. Function and regulation of the human multidrug resistance gene. Adv. Cancer Res., 60: 157-180, 1993.
4. Esteller, M., Martinez-Palones, J. M., Garcia, A., Xercavins, J., and Reventos, J. High rate of MDR1 and heterogeneous pattern of MRP expression without gene amplication in endometrial cancer. Int. J. Cancer, 63: 798-803, 1995.
5. Prau, W. B., Ruddon, R. W., Ensminger, W. D., and Maybaum, J. Resistance to anticancer drugs. In: W. B. Pratt, and R. W. Ruddon (eds.), The Anticancer Drugs, pp. 55-60. New York: Oxford University Press, 1994.
6. Gros, P., Ben Neriah, Y. B., Croop, J. M., and, Housman, D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (Lond.), 323: 728-732. 1986.
7. Sikic, B. I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol., 11: 1629-1635, 1993.
8. Solary, E., Caillot, D., Chauffert, B., Casanovas, R. O., Dumas, M., and Maynadie, M. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J. Clin. Oncol., 10: 1730-1736, 1992.
9. Berman, E., McBride, M., Lin, S., Menedez-Botet, C., and Tong, W. Phase 1 trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia (Baltimore), 9: 1631-1637, 1995.
10. List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dor, R., Salmon, S., Futscher, B., Baier, M., and Dalton, W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol., 11: 1652-1660. 1993.
11. Solary, E., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J. Y., Sadoun. A., Pignon, B., Berthou, C., Maloisel, F., Guyotat, D., Casassus, P., Ifrah, N., Lamy, Y., Audhuy, B., Colombat, P., and Harousseau, J. L. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88: 1198-1205, 1996.
12. Fisher, G. A., and Sikic, B. I. Drug resistance in clinical oncology and hematology. Introduction. Hematol. Oncol. Clin. N. Am., xi-xii, 1995.
13. Minuzzo, M., Marchni, S., Broggini, M., Faircloth, G., D'Incalci, M., and Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. USA, 97: 6780-6784, 2000.
14. Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA, 97: 6775-6779, 2000.
15. Goldsmith, M. E., Madden, M. J., Morrow, C. S., and Cowan, K. H. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J. Biol. Chem. 268: 5856-5860, 1993.
16. Sundseth, R., MacDonald, G., Ting, J., and King, A. C. DNA elements recognizing NF-Y and Sp-1 regulate the human multidrug-resistance gene promoter. Mol. Pharmacol., 51: 963-971, 1997.
17. Dorn, A., Bollekens, J., Staub, A., Benois, C., and Mathis, D. A multiplicity of CCAAT box-binding proteins. Cell, 50: 863-872, 1987.
18. Maity, S. N., Sinha, S, Ruteshouser, E. C., and de Crombrugghe, B. Three different polypeptides are necessary for DNA binding of the mammalian heteromeric CCAAT binding factor. J. Biol. Chem., 267: 16574-16580, 1992.
19. 1 protein and the CCAAT binding protein NF-Y. Mol. Cell. Biol., 17: 1236-1243, 1997.
20. Tanaka, H., Ohshima, N., and Hidaka, H. Isolation of cDNAs encoding cellular drug binding proteins using a novel expression cloning procedure: drug-western. Mol. Pharmacol., 55: 356-363, 1999.
21. Chomczynski, P., and Sacchi, N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
23. Hanania, E. G., Fu, S., Roninson, I., Zu, Z., and Deisseroth, A. B. Resistance to Taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther., 2: 279-284, 1995.
24. Ueda, K., Cardarelli, C., Gottesman, M. M., and Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastinc. Proc. Natl. Acad. Sci. USA, 84: 3004-3008, 1987.
25. Scotto, K. W., and Bertino, J. R. Chemotherapy susceptibility and resistance. In: J. Mendelsohn, Molecular Basis of Cancer Therapy, Philadelphia: W. B. Saunders, 468-485, 1995.
26. Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., Burt, M., and Scotto, K. W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res., 5: 3352-3356, 1999.
27. Li, S., Ku, C. Y., Farmer, A. A., Cong, Y. S., Chen, C. F., and Lee, W. H. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J. Biol. Chem., 273: 6183-6189, 1998.
28. Quimby, B. B., Wilson, C. A., and Corbett, A. H. The interaction between Ran and NTF2 is required for cell cycle progression. Mol. Cell. Biol., 11: 2617-2629, 2000.